Filing summary
Issuer discrepancy: The supplied filing is OncoCyte Corporation’s Form 10-Q, not a filing for Insight Molecular Diagnostics Inc. The summary below reflects OncoCyte’s filing.
Business context and reporting period
OncoCyte develops non-invasive blood-based cancer detection tests, with efforts focused on lung, bladder, and breast cancer. This unaudited 10-Q covers the quarter and six months ended June 30, 2017; financial amounts below are in U.S. dollars unless stated otherwise. On February 17, 2017, BioTime’s ownership fell below 50%, and OncoCyte was deconsolidated from BioTime, though it remained an affiliate. OncoCyte reports no revenue for the periods presented.
Financial performance and position
| Metric | Q2 2017 | Q2 2016 | Six months 2017 | Six months 2016 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Operating expenses / operating loss | $3.589m | $2.532m | $8.121m | $5.464m |
| Net loss | $3.804m | $2.543m | $8.509m | $5.471m |
| Basic and diluted loss per share | $0.13 | $0.10 | $0.29 | $0.22 |
Gross profit and gross margin are not presented; with no revenue, operating margins are not meaningful. Six-month R&D expense was $3.831m, general and administrative expense $3.158m, and sales and marketing expense $1.132m. No income tax provision or benefit was recorded.
At June 30, cash and cash equivalents were $8.644m and available-for-sale BioTime shares were valued at $1.113m. Total current assets were $10.269m, total assets $12.141m, current liabilities $4.686m, total liabilities $6.502m, and stockholders’ equity $5.639m. Current liabilities included $2.540m due to BioTime and affiliates. The bank loan had $2.0m original principal outstanding; its balance-sheet carrying value was $1.949m, split between $533,000 current and $1.416m noncurrent. Capital lease liabilities totaled $697,000.
For the six months, net cash used in operations was $6.571m; investing activities provided $879,000, mainly from BioTime share sales; and financing activities provided $4.162m, including $2.0m from warrant exercises and $2.0m of bank borrowing. Cash declined $1.530m from year-end 2016. The filing reports no off-balance-sheet arrangements.
Material changes and unusual items
- Compared with Q2 2016, Q2 2017 R&D expense rose 67.1% and sales and marketing expense rose 76.7%; G&A rose 4.5%. For the first six months, those categories increased 32.8%, 126.9%, and 51.8%, respectively.
- Management attributed higher R&D spending to lung-test development, headcount, stock compensation, and BioTime services; sales and marketing spending increased as the company prepared for a lung-test launch.
- Six-month G&A included a $1.084m noncash charge for warrants issued to induce investor warrant exercises. OncoCyte also recognized a $309,000 loss on sales of BioTime shares for the six-month period.
- On July 21, 2017, after quarter-end, warrant exercises generated approximately $5.74m gross proceeds. OncoCyte issued replacement warrants to purchase 1,496,923 shares; the proceeds are not included in June 30 cash.
- Prior-year expense categories were reclassified to show sales and marketing separately; the reclassification did not affect operating or net loss.
Outlook, risks, and contingencies
Management expects continued operating losses and negative cash flow, with significant R&D spending. It stated that available cash, securities, and working capital were sufficient for current operations through at least 12 months from issuance of the financial statements, but that additional capital would be needed to expand initial lung-test commercialization efforts during that period. No quantified revenue or earnings guidance was provided.
Commercialization depends on successful lung-test development, including CLIA and validation studies, and future sales and marketing investment. Management identified financing availability, potential shareholder dilution from equity issuance, and the need for Medicare or private-insurer reimbursement to support demand as important uncertainties. BioTime provides facilities and services under a shared-services agreement; amounts due are payable within 30 days, and proceeds from BioTime share sales are restricted to repaying BioTime-related amounts under the bank loan.
The bank loan bears a floating rate, is secured by substantially all assets other than intellectual property, and includes a contingent $3m tranche subject to conditions including raising at least $20m in additional equity and launching the initial lung test. The company reported compliance with the loan agreement and no known claims expected to have a material adverse effect. It disclosed possible severance obligations and broad contractual indemnification commitments, but recorded no indemnification liability.
Important facts for investors to verify
- Confirm the intended issuer: the supplied document is OncoCyte’s 10-Q, not Insight Molecular Diagnostics Inc.’s filing.
- Track progress and results of lung-test validation, regulatory or laboratory requirements, commercialization plans, and payer reimbursement efforts.
- Assess the cash-burn trajectory and the basis for management’s stated 12-month runway, including the effect of the post-quarter $5.74m warrant proceeds and ongoing funding needs.
- Review the dilution and accounting impact of the July 2017 replacement warrants and any subsequent equity or warrant transactions.
- Monitor BioTime-related payables and service allocations, restrictions on BioTime-share sale proceeds, and bank-loan covenants and repayment terms.